Telescope Innovations (TELI) Q1 2026 earnings summary

Executive summary

• Achieved record quarterly revenue of $2.7 million in Q1 FY2026, up from $1.2 million year-over-year.

• Growth driven by flagship DirectInject-LC product, first Self Driving Laboratory delivery, and increased contract research services.

• Strategic reinvestment of revenues to support operational expansion and innovation.

• Management affirms alignment with technical, strategic, and financial targets for FY2026.

Financial highlights

• Revenue increased to $2.7 million from $1.2 million in Q1 FY2025.

• Expenses rose to $3.92 million from $1.55 million year-over-year.

• Adjusted EBITA loss widened to $0.83 million from $0.10 million in Q1 FY2025.

Outlook and guidance

• Management expects continued momentum in product sales and strategic partnerships throughout 2026.

• Company remains confident in achieving annual technical, strategic, and financial objectives.